Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

Breast Cancer Clinical Trial

— i-GO  

Official title:

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03749850
• Other study ID #: NL67422.041.18
• Secondary ID: 2015-005582-23
• Status: Recruiting
• Phase: Phase 1
• Start date: March 2021
• Est. completion date: November 2022

Study information

• Verified date: February 2021
• Source: UMC Utrecht
• Contact: Mirjam A de Visser, MD
• Phone: +31(0)887563142
• Email: M.A.deVisser-30[@]umcutrecht.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this phase I feasibility study, the investigators evaluate the combination of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local hyperthermia and cyclophosphamide (C), for the local treatment of the primary breast tumour in patients with metastatic breast cancer.

When heated to 40-43 degrees Celsius (ºC), LTLD releases a very high concentration of doxorubicin locally within seconds. Hyperthermia of the primary tumour will be induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) on a dedicated Sonalleve MR-HIFU breast system.

The investigators hypothesize that by substituting doxorubicin (A) in the AC-chemotherapy regimen for the combination of LTLD and MR-HIFU induced hyperthermia, optimal local tumour control can be achieved without compromising systemic toxicity or efficacy.

This will be the first study to evaluate LTLD with MR-HIFU hyperthermia in breast cancer patients.

Description:

Advances in systemic treatment led to improved overall survival in patients with metastatic breast cancer. Various studies suggest that by obtaining loco-regional control, overall survival in advanced disease can further be improved.

Pre-operative chemotherapy can be used in metastatic breast cancer to make radical removal of the primary tumor feasible, while simultaneously maintaining control of already present metastatic sites. The doxorubicin and cyclophosphamide regimen (AC) is well-known both in (neo-)adjuvant setting as in treatment of metastatic breast cancer. At present, optimal local control in advanced breast cancer using adequate dosing of doxorubicin is hampered by its toxic systemic effects. Therefore the investigators aim to increase doxorubicin deposition in the primary tumor without interfering with systemic efficacy and toxicity, by combining lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local mild hyperthermia, induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU). When heated to 40-43 ºC, ThermoDox releases a very high concentration of doxorubicin locally within seconds. In the absence of hyperthermia, ThermoDox leads to a similar biodistribution and antitumor efficacy to free doxorubicin. MR-HIFU allows for controlled heating of deep-seated tumors.

This is a single-arm phase I feasibility study in 12 patients with de novo stage IV (distant metastasis at the time of diagnosis) her2-negative breast cancer, who have not received previous chemotherapy. The study treatment consists of up to 6 cycles at 21-day intervals of ThermoDox (50mg/m2) administered during MR-HIFU induced hyperthermia (60 minutes at 40-42 ᵒC) and cyclophosphamide (600 mg/m2) administered afterwards. A dedicated MR-HIFU breast system integrated with a clinical 1.5 Tesla Magnetic Resonance Imaging (MRI) scanner will be used for safe and controlled heating of the tumour. Primary endpoints are safety, tolerability and feasibility. Secondary endpoint is efficacy, assessed by radiological response of the local tumor and the distant metastases.

In the Biobank side study, extra blood samples will be collected. These samples will be used for further research on not yet determined topics related to breast cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: November 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients must meet all of the following inclusion criteria:

1. Histologically confirmed adenocarcinoma of the breast and planned for palliative chemotherapy with doxorubicine en cyclophosphamide

2. Biopsy-proven stage tumor 1-2, any nodes, metastasis 1 (T1-2AnyNM1) at diagnosis of breast cancer.

3. Non-pregnant, non-lactating female at least 18 years of age. If patient is of child-bearing age, she must have a negative serum pregnancy test prior to enrollment and must agree to practice an acceptable form of birth control while on study.

4. The tumor is located within the reach of the HIFU beam (based on pre-treatment Dynamic Contrast Enhanced (DCE-) MRI findings).

5. The distance of the tumor from the skin, nipple, and pectoral wall is at least 1.0 cm (based on pre-treatment DCE-MRI findings).

6. The target breast is expected to fit in the cup of the dedicated MR-HIFU breast system (based on pre-treatment MRI findings).

7. The patient weighs less than 90 kg (restrictment of the HIFU table top).

8. Provide written informed consent and willing to comply with protocol requirements.

Exclusion Criteria:

Patients will be excluded if any of the following conditions are observed:

1. Her2-positive disease or classic invasive lobular carcinoma (ILC).

2. A treatment plan with curative intent is available.

3. Any prior chemotherapy treatment for invasive breast cancer (previous anti-hormonal therapy is allowed)

4. Any prior therapy with anthracyclines

5. No measurable disease at baseline (according to RECIST 1.1 or PERCIST 1.0)

6. Any concomitant malignancy or previous malignancy in the last 5 years, except basal cell or squamous cell cancer of the skin or in situ carcinoma of the cervix.

Subjects with a prior contralateral breast malignancy more than 5 years ago can be included if they did not receive any chemotherapy.

7. Any previous malignancy in the unilateral breast (even if more than 5 years ago)

8. Prior sensitivity (including rash, dyspnea, wheezing, urticarial, or other symptoms) attributed to any liposomal-encapsulated drug.

9. Baseline laboratory values:

Absolute Neutrophil Count (ANC) < 1.5 x 10^9/L, Platelets < 75 x 10^9/L, Hemoglobin < 5.6 mmol/L (9 g/dl), Total Bilirubin > 1.5 x upper limit of normal, Alanine Transaminase (ALAT) and Aspartate Transaminase (ASAT) > 2.5 x upper limit of normal >5 x upper limit of normal in case of liver metastases, Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73m2.

10. World Health Organization Performance Status (WHO-PS) >2.

11. Left Ventricular Ejection Fraction <50% (validated by baseline scan).

12. History of:

1. Acute coronary syndrome in the last year

2. Cerebral vascular accident in the last year

3. Abnormal cardiac stress testing within last 6 months

4. Symptomatic coronary artery disease

5. Uncontrolled hypertension or cardiomyopathy

6. Cardiac valvular surgery or open heart surgery in the last year

7. Known structural heart disease

13. Any condition which may interfere with the hyperthermia portion of the trial such as:

functioning cardiac pacemaker; metal plates, rods or prosthesis of the chest wall, breast prosthesis in the treated breast, severe numbness and/or tingling of the chest wall or breast, skin grafts and/or flaps on the breast or chest wall, scar tissue or surgical clips in the HIFU beam path.

14. Active infection

15. Body temperature > 38.0 degrees Celsius on the day of a MR-HIFU treatment.

16. Concurrent use of any of the following prohibited medications within a reasonable wash-out time: protease inhibitors, cyclosporine, carbamazepine, phenytoin, valproic acid, paclitaxel, trastuzumab and other liposomal drugs (Abelect, Ambisome, Nyotran, etc.) or lipid-complexed drugs.

17. Caution will be exercised with all the medications mentioned in appendix C, for interactions are theoretically possible.

18. Contraindications to MR imaging (e.g., pacemaker in situ, severe claustrophobia, metal implants incompatible with the MRI-scan, body size incompatible with MR bore).

19. Contraindications to gadolinium-based contrast agent, including prior allergic reaction to gadolinium-based contrast agent, and/or renal failure.

20. Contraindications to sedation and analgesia with propofol and Remifentanil, including history of Chronic Obstructive Pulmonary Disease (COPD) that results in the inability to perform a physical activity corresponding with a Metabolic Equivalent (MET(57)) of 4; dependence on artificial ventilation at home; sleep apnea or an American Society of Anesthesiologists (ASA) classification =4.

21. Inability to lie in prone position.

22. A medical or psychiatric condition or other circumstances which would significantly decrease the chances of understanding the informed consent process, obtaining reliable data, achieving study objectives, or completing the study treatment and/or examinations.

Related Conditions & MeSH terms

• Adenocarcinoma Breast
• Breast Cancer
• Breast Neoplasms
• Carcinoma, Ductal
• Carcinoma, Ductal, Breast
• Fever
• Invasive Ductal Breast Cancer
• Invasive Ductal Carcinoma of Female Breast
• Metastatic Breast Cancer
• Metastatic Cancer
• Stage IV Breast Cancer

Intervention

Drug:
• LTLD
Patients will receive up to six cycles at three-weeks intervals of: Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol.

Procedure:
• MR-HIFU induced hyperthermia
Patients will receive up to six cycles at three-weeks intervals of: - 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour. In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol.

Drug:
• Cyclophosphamide
Patients will receive up to six cycles at three-weeks intervals of: - Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol.

Locations

Country	Name	City	State
Netherlands	University Medical Center Utrecht	Utrecht

Sponsors (4)

Lead Sponsor	Collaborator
UMC Utrecht	Center for Translational Molecular Medicine, Dutch Cancer Society, Vrienden UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events assessed by CTCAE v 5.0	Safety and tolerability of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	Incidence of dose limiting toxicities	Safety and tolerability of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	Incidence of necessity for dose adjustments, delay or early cessation	Safety and tolerability of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	Incidence and severity of post-procedural pain	Safety and tolerability of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	Patient reported tolerability via an adapted version of the Cancer Therapy Satisfaction Questionnaire (CTSQ)	Tolerability of the study treatment. Scores will be described.	Baseline, day 49 and day 112
Primary	Patient reported tolerability via the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire	Tolerability of the study treatment. Scores will be described.	Baseline, and on day 14 of each cycle (with a maximum of six 21-day cycles in 18 weeks)
Primary	Incidence of cardiotoxity	Safety and tolerability of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	Description of MR thermometry data (describing the temperatures achieved)	Feasibility of the study treatment	On day 1 (study treatment day) of each cycle (with a maximum of six 21-day cycles in 18 weeks)
Primary	Duration of procedures on a treatment day	Feasibility of the study treatment	On day 1 (study treatment day) of each cycle (with a maximum of six 21-day cycles in 18 weeks)
Primary	Number of completed cycles with MR-HIFU induced hyperthermia, ThermoDox and cyclophosphamide	Feasibility of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Primary	The number of cycles in which hyperthermia was sufficient: at least 30 minutes at the target temperature of 40-42°C	Feasibility of the study treatment	From first study treatment (day 1) until the end of study visit between day 161 and 175
Secondary	Radiological objective response locally on breast Magnetic Resonance Imaging, assessed by RECIST 1.1.	Efficacy of the study treatment	Assessed after 2 cycles and after 6 cycles of the study treatment. Each cycle is 21 days.
Secondary	Radiological objective response systemically on Computed Tomography, assessed by RECIST 1.1 or (for patients without RECIST-measurable disease) Positron Emission Tomography Computed Tomography, assessed by PERCIST 1.0	Efficacy of the study treatment	Assessed after 2 cycles and after 6 cycles of the study treatment. Each cycle is 21 days.